DEA No. 9720 en es it fr

DEA No. 9720 Brand names, DEA No. 9720 Analogs

DEA No. 9720 Brand Names Mixture

  • No information avaliable

DEA No. 9720 Chemical_Formula


DEA No. 9720 RX_link

DEA No. 9720 fda sheet

DEA_No._9720 FDA

DEA No. 9720 msds (material safety sheet)

DEA_No._9720 MSDS

DEA No. 9720 Synthesis Reference

No information avaliable

DEA No. 9720 Molecular Weight

327.461 g/mol

DEA No. 9720 Melting Point

No information avaliable

DEA No. 9720 H2O Solubility


DEA No. 9720 State


DEA No. 9720 LogP


DEA No. 9720 Dosage Forms

Drops; Drug premix; Gel; Globules; Liquid; Powder for solution; Solution; Spray; Tablet

DEA No. 9720 Indication

For the management of pain when the use of an opioid analgesic is appropriate. Also indicated as a preoperative or preanesthetic medication, as a supplement to balanced anesthesia, and for the relief of pain during labor.

DEA No. 9720 Pharmacology

Butorphanol is a synthetic opioid agonist-antagonist analgesic with a pharmacological and therapeutic profile that has been well established since its launch as a parenteral formulation in 1978. The introduction of a transnasal formulation of butorphanol represents a new and noninvasive presentation of an analgesic for moderate to severe pain. This route of administration bypasses the gastrointestinal tract, and this is an advantage for a drug such as butorphanol that undergoes significant first-pass metabolism after oral administration. The onset of action and systemic bioavailability of butorphanol following transnasal delivery are similar to those after parenteral administration. Butorphanol blocks pain impulses at specific sites in the brain and spinal cord.

DEA No. 9720 Absorption

Rapidly absorbed after intramuscular injection and peak plasma levels are reached in 20-40 minutes. The absolute bioavailability is 60-70% and is unchanged in patients with allergic rhinitis. In patients using a nasal vasoconstrictor (oxymetazoline) the fraction of the dose absorbed was unchanged, but the rate of absorption was slowed. Oral bioavailability is only 5-17% because of extensive first-pass metabolism.

DEA No. 9720 side effects and Toxicity

The clinical manifestations of butorphanol overdose are those of opioid drugs in general. The most serious symptoms are hypoventilation, cardiovascular insufficiency, coma, and death.

DEA No. 9720 Patient Information

DEA No. 9720 Organisms Affected

Humans and other mammals